DAX24.853 ±-0,0%Est506.011 -0,4%MSCI World4.343 -0,1%Top 10 Crypto8,4100 -3,5%Nas22.648 -1,8%Bitcoin55.271 -2,0%Euro1,1864 -0,1%Öl67,33 -3,3%Gold4.938 -2,9%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Siemens Energy ENER6Y Siemens 723610 Mercedes-Benz Group (ex Daimler) 710000 SAP 716460 Deutsche Telekom 555750 Rheinmetall 703000 NVIDIA 918422 BASF BASF11 Gerresheimer A0LD6E Lufthansa 823212 Amazon 906866 Microsoft 870747 Allianz 840400 Bayer BAY001 DroneShield A2DMAA
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX letztlich kaum bewegt -- Mercedes-Benz: Gewinneinbruch -- Siemens erhöht Ergebnisprognose -- TKMS, Deutsche Börse, DroneShield, Lufthansa, Birkenstock, Micron, Palantir, Fastly im Fokus
Top News
Ausblick: Coinbase präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel Ausblick: Coinbase präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel
Risikolebensversicherung - Gut versichert im Eigenheim Risikolebensversicherung - Gut versichert im Eigenheim
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Noch bis 14. April bei der Commerzbank gebührenfrei in Vanguard-ETFs investieren

Johnson Johnson Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
206,15 EUR +3,30 EUR +1,63 %
STU
244,75 USD +3,92 USD +1,63 %
BTT
Johnson Johnson jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.483,71 Mrd. EUR

KGV18,82Div. Rendite2,48%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN853260

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS4781601046

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolJNJ

Johnson Johnson Aktien News

DatumMeistgelesen
EN, Johnson & JohnsonJohnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium
EN, Johnson & JohnsonJohnson & Johnson Highlights New Scientific Evidence and Reinforces its Leadership with Portfolio Advancements at AF Symposium
EN, Johnson & JohnsonJohnson & Johnson Releases Report on Surgeon Burnout as More than 40% Surveyed Consider Leaving the Profession
Wer­bungJohnson Johnson-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
EN, Johnson & JohnsonDARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
EN, Johnson & JohnsonJohnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile
EN, Johnson & JohnsonJohnson & Johnson reports Q4 and Full-Year 2025 results
EN, Johnson & JohnsonNew clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder
EN, Johnson & JohnsonJohnson & Johnson Introduces Mobile Simulator App to Support Breast Augmentation Patients
EN, Johnson & JohnsonJohnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
EN, Johnson & JohnsonRYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
PR NewswireRYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
EN, Johnson & JohnsonJohnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments
EN, Johnson & JohnsonJohnson & Johnson celebrates innovation in cancer research with 2025 Dr. Paul Janssen Award
EN, Johnson & JohnsonJohnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration
EN, Johnson & JohnsonJohnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study
PR NewswireJohnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study
EN, Johnson & JohnsonJohnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies
EN, Johnson & JohnsonEuropean Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor
EN, Johnson & JohnsonJohnson & Johnson Backs HRS Registry to Advance Real-World Evidence in PFA
EN, Johnson & JohnsonJohnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
PR NewswireJohnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
PR NewswireU.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (la...
EN, Johnson & JohnsonU.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
PR NewswireU.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
PR NewswireUnprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multip...
EN, Johnson & JohnsonEarlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
PR NewswireEarlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
EN, Johnson & JohnsonJohnson & Johnson’s INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
PR NewswireJohnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
EN, Johnson & JohnsonJohnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40
PR NewswireJohnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40
EN, Johnson & JohnsonNew long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
PR NewswireNew long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
EN, Johnson & JohnsonJohnson & Johnson set to revolutionize the treatment of cancer with the acquisition of Halda Therapeutics
EN, Johnson & JohnsonDARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
PR NewswireDARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
EN, Johnson & JohnsonFDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
PR NewswireFDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
EN, Johnson & JohnsonJohnson & Johnson reinforces its leadership in hematology at ASH 2025 unveiling new paradigm-shifting research
EN, Johnson & JohnsonJohnson & Johnson One Year Data Demonstrate Durable Performance and Safety of the Shockwave Javelin Peripheral IVL Catheter in Late-Breaking Presentation at VIVA 2025

Johnson Johnson News

Johnson Johnson News: auf dieser Seite finden Sie alle Johnson Johnson News und Nachrichten zur Johnson Johnson Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Johnson Johnson News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Johnson Johnson News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.